Our Mission - Provide supercritical CO2 knowledge, services and tools to all companies focused on a healthier world.
Equipment for today's needs and R&D services for tomorrow's opportunities
Allograft to xenograft tissue market served as the commercial launch for NovaSteirilis. Today the Nova2200 and Nova8800 platforms clean and/or sterilize a variety of biomaterials including dermis, tendons, amnion, bone, hyaluron, collagen, cellulose, alginates and silk to name a few. The Nova Process achieves industry standard sterility assurance levels of SAL6 and has been the terminal sterilization modality of choice for devices approved by both the TGA and FDA.
Efforts in drug delivery and regenerative medicine have focused on combination devices; sensitive polymers with biologic factors or bio-scaffolds impregnated with a therapeutic. These devices are often manufactured aseptically because no terminal sterilization solution exists. Development efforts have centered on constructs such as heart valves, arterial conduits hyaluronic acid and bone crunch impregnated with bioactives and endospores inoculated with therapeutics for treatment of solid tumors.
The Nova Process has been vetted as a terminal sterilization modality on small molecule APIs with no impact to physical properties or biological function. Additionally, a process to extract residual ethylene oxide from finished APIs has been patented. Large molecule treatments are not only limited to sterility but it also included a process for the creation of vaccines. This is a focus area of development for NovaSterilis with a desire to grow the number of active partnerships.
As scCO2 becomes more widely recognized, and the low temperature, non-reactive, penetrating attributes of the material are better appreciated, envisioned applications have grown dramatically. Despite many materials being compatible with scCO2 it can cause problems with structure and function, so NovaSterilis has evaluated hundreds of materials as well as devices (combination materials) ranging from drug eluting polymers to single use syringes to multi-use, complex devices such as endoscopes.
As a co-founder Tony acted as Chairman until November 2017 when he took on the role as president and CEO. Tony’s focus is to expand the use of the NovaSterilis platform through customer support, partnerships and collaborative developments. Prior to joining the company fulltime, Tony served as the managing director of KensaGroup, which creates and operates startups spun out of university research. Additionally, he was the CEO of a mid-market manufacturer and vice president of a multi-billion retailer. Tony earned his B.S. degree from Cornell University.
Director of Engineering
Gus joined the team in November 2017 with a mission to support customer equipment use and to develop platforms that meet the emerging customer needs. He joined from Mettler Toledo where he was a senior electrical engineer trained in Lean manufacturing. His mechanical and electrical engineering experiences range from radar installations to high pressure fuel reactors. Gus’ six years in the Navy trained him to realize nothing is outside of his job description when it comes to satisfying the customer. Gus earned two B.S. degrees from ECPI University.
Director of Applications
Julien joined the team in 2014 to lead scCO2 applications development and support emerging customer needs for scCO2 sterilization and novel product creation. He brings a collaborative style to customer research projects overlaying the commercial mandates of the business on the scientific question being researched. Julien joined from Agave BioSystems where he served as a senior scientist and prior to that he was a senior researcher at Cornell University. Julien earned his Ph.D. from Universite Louis Pasteur and completed post docs at Oregon Health and Science University and Cornell University.